A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis
Neurology 2012;78;840-841
DOI 10.1212/01.wnl.0000413180.13413.ce

This information is current as of March 12, 2012

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://www.neurology.org/content/78/11/840.2.full.html
A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis

Neurology 2012;78;840-841
DOI 10.1212/01.wnl.0000413180.13413.ce

This information is current as of March 12, 2012

Updated Information & Services
including high resolution figures, can be found at:
http://www.neurology.org/content/78/11/840.2.full.html

References
This article cites 6 articles, 4 of which you can access for free at:
http://www.neurology.org/content/78/11/840.2.full.html##ref-list-1

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://www.neurology.org/misc/addir.xhtml#reprintsus
THROMBOLYSIS OUTCOMES IN ACUTE ISCHEMIC STROKE PATIENTS WITH PRIOR STROKE AND DIABETES MELLITUS

Gaetano Santulli, New York: Mishra et al. examined the influence of diabetes mellitus and prior stroke on the outcomes of patients who received thrombolysis vs nonthrombolyzed controls. They found no interaction on outcome between diabetes and prior stroke with thrombolysis treatment.

These results conflict with the European Medicines Evaluation Agency’s justification for restricting the use of IV alteplase. As Dr. Demaerschalk mentioned in the accompanying editorial, recent studies have suggested that thrombolysis can be safely used in several groups of patients who do not qualify for treatment due to strict application of exclusion criteria.

In addition, most of the commonly cited thrombolytic exclusion criteria are just consensus-based, not evidence-based. It is time to reevaluate the criteria for thrombolysis, adopting a clinical score to stratify the risk, similar to those used in acute coronary syndrome. A good risk assessment tool will be able to identify a gradient of mortality risk by using variables that capture the majority of prognostic information to better evaluate the risk/benefit ratio for each patient.

Copyright © 2012 by AAN Enterprises, Inc.


A RANDOMIZED TRIAL OF HIGH-DOSE VITAMIN D2 IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

Helmut H. Leitner, Vienna: Stein et al. compared high- vs low-dose vitamin D2 treatment in MS without benefit in the high-dose treatment group. Sunlight exposure and reduced vitamin D3 levels independently contribute to MS risk. The effect of sunlight exposure is supported by decreased signs of actinic skin damage found in MS patients compared to controls. It is difficult to determine which of these 2 environmental factors is of primary importance as higher levels of sunlight exposure will enhance vitamin D levels.

The incidence of vitamin D–related rickets disease decreased in the United States and Europe during the last century following the discovery that vitamin D possessed antirachitic properties, whereas the incidence of MS seemed to increase in the same population. In the United States, most of the patients with rickets are African American, whereas the majority of patients with MS are of European ancestry. It seems improbable that the same environmental factor should be centrally involved in the etiology of both diseases, which differ clinically and occur in different populations living in the same geographic area.

These findings together with those of Stein et al. do not provide a reason for vitamin D supplementa-
tion in MS aside from correcting a proven vitamin D deficiency. Other factors associated with increased sunlight exposure may more effectively prevent MS.

L. Grimaldi, Cefalù, Italy; F. Barkhof, Amsterdam; M. Beelke, Gauting–Unterbrunn, Germany; J. Burton, Calgary, Canada; T. Holmoy, Oslo; R. Hupperts, Sittard, the Netherlands; J. Killestein, Amsterdam; P. Rieckmann, Würzburg, Germany; M. Schluep, Lausanne, Switzerland; J. Smolders, Amsterdam; on behalf of the SOLAR study group:

The conclusion of Stein et al.1 that high-dose ineffectual vs low-dose vitamin D2 supplementation in relapsing-remitting MS (RRMS) is not supported by data enabling level 1 evidence.

Randomization to interferon-β, glatiramer acetate, or no treatment results in very small treatment groups. Such MRI-based randomized placebo-controlled trials would need at least 85 patients per arm to reach statistical significance, assuming 50% treatment difference4 and, since vitamin D effects may appear after 12–24 weeks, an MRI follow-up period of at least 9—not 6—months.

In figure 2, only 4/11 subjects in the higher dose group exhibited 25(OH)D levels within the 130–175 nmol/L target range.1 Since dosages must have been adjusted continuously throughout the trial, likely fluctuations in serum 25(OH)D prevent firm conclusions.5

During the study, MKTVIF75HV (vitamin D2) was replaced by vitamin D3. As vitamin D2 and D3 are not equivalent,5 these results cannot be extended to all “vitamin D” subtypes.

To address these issues, an appropriately powered, randomized, double-blind, placebo-controlled, phase II study (SOLAR) of high-dose vitamin D3 (vigantol oil, 14,000 IU/d) add-on to interferon β–1a, 44 μg subcutaneously 3 times weekly (Rebif), for 96 weeks in 348 RRMS patients, is currently under way.6

The SOLAR study group also includes Reinhold Vieth (SC member), Lizette Ghazi (SC member), Klemens Angtsturm, Simone Cursiefen, Ana Martins de Silva, Jan–Markus Dörr, Irina Elovaara, Juha-Pekka Erälinna, Markus Färkkilä, Masoud Falah, Jette Frederiksen, Steven Frequin, Claudio Gobbi, Bernd Griewling, Katrin Gross-Paju, Elisabeth Gulowsen Celius, Christina Känder, Claudia Kaiser, Jolanta Kalnina, Christian Kamm, Margitta Kampman, Keijo Koivistö, Samuel Komoly, Christian Lamp, Dalia Mickevičienė, Kjell-Morten Myhr, Lina Malcioni, Michael Linnebank, Martin Marziniak, Sabine Urbanits, László Vecsei, Freek Verheul, and Uwe K. Zettl.

Copyright © 2012 by AAN Enterprises, Inc.


Author disclosures are available upon request (journal@neurology.org).